Tesamorelin + Ipamorelin 30mg Vial Bali

Rp3,800,000.00 ~$230.30

Explore the Atlas Longevity Tesamorelin + Ipamorelin Blend 30mg, an experimental dual-peptide formulation combining two compounds associated with growth hormone signalling research.

Each vial contains:

  • Tesamorelin: 20mg
  • Ipamorelin: 10mg
  • Total labelled content: 30mg
  • Ratio: 2:1 by mass
  • Format: Research peptide vial
  • Research Area: Growth hormone and endocrine signalling

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue, while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor.

For laboratory research purposes only. Not for human consumption.

Your vial includes 3ml Bac Water + 6 Syringes + 6 Alcohol Pads.
20%
WELCOME OFFER Get 20% Off Your Order

Use code WELCOME20 at checkout. Valid for the first 100 orders only.

Available on backorder

Description

Tesamorelin + Ipamorelin Blend 30mg Bali

Dual Growth Hormone Signalling Research Blend

The Tesamorelin 20mg + Ipamorelin 10mg Blend combines two peptides with distinct mechanisms associated with growth hormone release.

Tesamorelin acts through the GHRH receptor, while ipamorelin acts through the growth hormone secretagogue receptor, also known as GHS-R1a.

The individual compounds have been investigated in endocrine research, but the safety and effectiveness of this specific 30mg combination have not been established in adequate human clinical trials.

What’s Inside the 30mg Blend?

Ingredient Quantity Research Focus
Tesamorelin 20mg GHRH receptor and growth hormone signalling
Ipamorelin 10mg Ghrelin receptor and growth hormone secretagogue signalling
Total 30mg Experimental dual-peptide formulation

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone.

It stimulates growth hormone release through GHRH receptor activity.

A specific pharmaceutical formulation of tesamorelin is approved in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

That approval does not extend automatically to independently manufactured tesamorelin vials, other indications or tesamorelin-ipamorelin blends.

Tesamorelin research has included:

  • Growth hormone secretion
  • IGF-1 signalling
  • Visceral adipose tissue measurements
  • Endocrine regulation
  • Metabolic outcomes

What Is Ipamorelin?

Ipamorelin is an experimental peptide that acts as an agonist at the growth hormone secretagogue receptor.

It has been investigated for its ability to influence growth hormone release.

Research areas include:

  • Growth hormone secretagogue activity
  • Ghrelin receptor signalling
  • Endocrine responses
  • Pituitary hormone regulation
  • Growth hormone pulse dynamics

Ipamorelin is not an established approved treatment for muscle growth, fat loss or recovery.

Tesamorelin + Ipamorelin Research Areas

The individual compounds have been investigated in relation to:

  • Growth hormone signalling
  • GHRH receptor activity
  • Ghrelin receptor activity
  • IGF-1 regulation
  • Endocrine responses
  • Metabolic pathways
  • Body composition research

These areas do not demonstrate that combining tesamorelin and ipamorelin produces greater benefits than either compound individually.

Tesamorelin vs Ipamorelin

Feature Tesamorelin Ipamorelin
Compound Class GHRH analogue Growth hormone secretagogue
Primary Receptor GHRH receptor GHS-R1a
Main Research Area GH and IGF-1 signalling GH secretagogue signalling
Quantity in Blend 20mg 10mg

Although the compounds act through different receptors, additive or synergistic effects of this specific blend have not been clinically established.

Product Specifications

Product: Tesamorelin + Ipamorelin Blend

Brand: Atlas Longevity

Tesamorelin Content: 20mg

Ipamorelin Content: 10mg

Total Labelled Content: 30mg

Ingredient Ratio: 2:1 by mass

Format: Research peptide vial

Category: Hormone Optimization

Classification: Experimental peptide combination

Intended Use: Laboratory research only

Quality & Batch Documentation

Contact Atlas Longevity to request available batch-specific analytical documentation.

For blended peptide products, appropriate testing should identify and quantify both compounds where validated methods permit.

Purity testing alone does not establish sterility, clinical safety or pharmaceutical approval.

Storage

Follow the verified storage instructions supplied for the specific batch.

Protect from excessive heat, moisture, direct sunlight and contamination.

The stability and compatibility of tesamorelin and ipamorelin in a combined formulation, particularly after reconstitution, require formulation-specific evidence.

Safety Information

Tesamorelin can increase IGF-1 levels and may affect glucose regulation. Approved tesamorelin formulations carry warnings and require medical monitoring.

The safety profile of ipamorelin remains inadequately established.

Potential interactions, adverse effects and long-term risks of this combined formulation are not sufficiently characterised.

Atlas Longevity Bali

Atlas Longevity provides information about experimental peptides and endocrine research.

Contact our support team for product specifications, batch documentation and regulatory information.

Any supply is subject to applicable Indonesian regulations.


Frequently Asked Questions

What is Tesamorelin + Ipamorelin Blend?

It is an experimental dual-peptide formulation combining tesamorelin, a GHRH analogue, with ipamorelin, a growth hormone secretagogue.

How much peptide is in each vial?

Each vial contains 30mg total labelled peptide content: 20mg tesamorelin and 10mg ipamorelin.

What is Tesamorelin researched for?

Tesamorelin has been studied for growth hormone and IGF-1 signalling, metabolic outcomes and visceral adipose tissue measurements.

What is Ipamorelin researched for?

Ipamorelin has been investigated for its effects on growth hormone secretion through the ghrelin receptor.

What is the difference between Tesamorelin and Ipamorelin?

Tesamorelin activates GHRH receptors, while ipamorelin activates growth hormone secretagogue receptors. They influence growth hormone signalling through different mechanisms.

Is Tesamorelin + Ipamorelin the same as CJC-1295 + Ipamorelin?

No. Tesamorelin and CJC-1295 are different GHRH-related peptides. These blends have different compositions and cannot be assumed to have equivalent effects.

Does Tesamorelin + Ipamorelin increase growth hormone?

Both ingredients have been investigated for growth hormone-related activity, but the response and safety of this specific combined formulation have not been adequately established.

Is Tesamorelin + Ipamorelin proven to reduce belly fat?

No. Although a specific pharmaceutical formulation of tesamorelin has an approved indication for HIV-associated abdominal fat, that evidence does not establish effectiveness for this blend or general abdominal fat reduction.

Is Tesamorelin + Ipamorelin approved for medical use?

No. This combined formulation is not an established approved medical treatment.

Is this blend suitable for injection?

A labelled strength or purity test alone cannot establish sterility, safety or suitability for injection.

Is a Certificate of Analysis available?

Contact Atlas Longevity for available batch-specific analytical documentation.

Can the two peptides be stored together?

Compatibility and stability in a single vial require formulation-specific evidence and should not be assumed from data on the individual compounds.


Research Disclaimer

For laboratory research purposes only. Not for human consumption.

Tesamorelin and ipamorelin are pharmacologically active peptides. The safety, effectiveness and stability of this combined 30mg formulation have not been established for human administration.

This product is not intended to diagnose, treat, cure or prevent any disease.

Benefits
  • Synergistic mechanism — research suggests GHRH + GHRP combinations can produce amplified GH pulses compared to either alone
  • Body composition research — clinical trials of Tesamorelin have investigated effects on visceral adipose tissue in specific patient populations
  • Selective GHRP profile — published research indicates Ipamorelin has minimal effect on cortisol or prolactin at research doses
  • Customer reports — users on our protocol commonly describe improvements in sleep quality, recovery, and body composition over 12-week research cycles; results vary individually
  • IGF-1 axis research — published studies have explored GHRH/GHRP effects on IGF-1 and downstream anabolic signalling
  • Research use only — for in-vitro and laboratory research applications